A postmarketing observational study to assess respiratory tract adverse events in pulmonary arterial hypertension patients treated with Tyvaso® (treprostinil) inhalation solution

Investigator: Vijay P. Balasubramanian, MD, MRCP
Sponsor: United Therapeutics Corporation

Location(s): United States


A surveillance of respiratory tract related adverse events in patients treated with Tyvaso®(treprostinil) Inhalation Solution versus other FDA approved therapies. A comparison will be made to the type and incidence of events in patients receiving other FDA approved therapies for pulmonary arterial hypertension, as a control measure.